Proton Therapy Publication Proton Therapy Publication
Menu

Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer.

March 2023
Executive summary

With data of 41 patients with stage III NSCLC who received PBT of 74 GyE with concurrent chemotherapy, this study reported that bone V5-20 and lung V5-50 were significantly correlated with minimum absolute lymphocyte count (ALCmin) and maximum neutrophil/lymphocyte ratio (NLRmax)  during PBT. NLRmax was associated with OS, PFS and distant metastasis-free survival (DMFS). The 3-year rates of OS, PFS and DMFS of patients with a low (≤ 6.3) versus high (> 6.3) NLRmax were 73.9% vs 44.4% (P = 0.042), 26.1% vs 5.6% (P = 0.022) and 39.1% vs 5.6% (P < 0.001), respectively. 

Key content topics
Chemotherapy
Survival
Top cancer treatments
Thoracic

Related contents

Proton Therapy Publication
April 2023
Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
en
Link to the fully detailed content
Proton Therapy Publication
July 2022
Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 1/2 Trial.
en
Link to the fully detailed content
Proton Therapy Publication
April 2022
A Comparative Analysis of Photon versus Proton Beam Therapy in Neoadjuvant Concurrent Chemoradiotherapy for Intrathoracic Squamous Cell Carcinoma of the Esophagus at a Single Institute.
en
Link to the fully detailed content
Proton Therapy Publication
Proton therapy publication
February 2022
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
Link to the fully detailed content
Proton Therapy Publication
Proton therapy publication
November 2021
Preliminary Safety and Efficacy of Proton Plus Carbon-Ion Radiotherapy With Concurrent Chemotherapy in Limited-Stage Small Cell Lung Cancer.
Link to the fully detailed content